Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...

Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its blockbuster molecule tirzepatide. | Eli Lilly has invested heavily into obesity, ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...

Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...